tibljТуберкулез и болезни легкихTuberculosis and Lung Diseases2075-12302542-1506Медицинские знания и технологии10.58838/2075-1230-2024-102-1-72-81tiblj-1797Research ArticleОБЗОРREVIEWСтратегия «терапии хозяина» при туберкулезе. Значение интерферона гамма в патогенезе и терапии туберкулезной инфекцииStrategy of the Host-Directed Therapy for Tuberculosis: the Importance of Interferon-Gamma in the Pathogenesis and Therapy of Tuberculosis InfectionМожокинаГ. Н.MozhokinaG. N.

Можокина Галина Николаевна, д.м.н., ведущий научный сотрудник научной лаборатории иммунопатологии и иммунодиагностики туберкулезной инфекции 

127473, г. Москва, ул. Достоевского, д. 4

Galina N. Mozhokina, Doctor of Medical Sciences, Leading Researcher of Research Laboratory of Immunopathology and Immunodiagnostics of Tuberculosis Infection 

4 Dostoevsky St., Moscow, 127473

mojokina@mail.ruСамойловаА. Г.SamoylovaA. G.

Самойлова Анастасия Геннадьевна, д.м.н., заместитель директора по научной работе 

127473, г. Москва, ул. Достоевского, д. 4

Anastasiya G. Samoylova, Doctor of Medical Sciences, Deputy Director for Research 

4 Dostoevsky St., Moscow, 127473

a.samoilova.nmrc@mail.ruАбрамченкоА. В.AbramchenkoA. V.

Абрамченко Анна Валентиновна, младший научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций

127473, г. Москва, ул. Достоевского, д. 4

Anna V. Abramchenko, Junior Researcher of Research Department of Differential Diagnosis and Treatment of Tuberculosis and Concurrent Infections

4 Dostoevsky St., Moscow, 127473

av.abramchenko@mail.ruhttps://orcid.org/0000-0002-4132-0049РомановаМ. И.RomanovaM. I.

Романова Мария Игоревна, младший научный сотрудник 

127473, г. Москва, ул. Достоевского, д. 4

Maria I. Romanova, Junior Researcher

4 Dostoevsky St., Moscow, 127473

RomanovaMI@nmrc.ruhttps://orcid.org/0000-0002-0637-7955ВасильеваИ. А.VasilyevaI. A.

Васильева Ирина Анатольевна, д.м.н., профессор, директор, заведующая кафедрой фтизиатрии ФГАОУ ВО «РНИМУ им. Н. И. Пирогова» МЗ РФ

127473, г. Москва, ул. Достоевского, д. 4

Irina A. Vasilyeva, Doctor of Medical Sciences, Professor, Director, Head of Phthisiology Department, Pirogov Russian National Research Medical University, Russian Ministry of Health 

4 Dostoevsky St., Moscow, 127473

vasil33@list.ruФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФРоссияNational Medical Research Center of Phthisiopulmonology and Infectious Diseases, Russian Ministry of HealthRussian Federation20242003202410217281Copyright © Можокина Г.Н., Самойлова А.Г., Абрамченко А.В., Романова М.И., Васильева И.А., 20242024Можокина Г.Н., Самойлова А.Г., Абрамченко А.В., Романова М.И., Васильева И.А.Mozhokina G.N., Samoylova A.G., Abramchenko A.V., Romanova M.I., Vasilyeva I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.tibl-journal.com/jour/article/view/1797

В обзоре приведен анализ 69 источников литературы для обсуждения вопросов лечения лекарственно-устойчивого туберкулеза с позиций влияния на иммунные механизмы, ограничивающие прогрессирование воспаления и повреждение легочной ткани. Наиболее важным цитокином в патогенезе туберкулезной инфекции является интерферон-гамма. Показаны генотипические и фенотипические особенности продукции интерферона-гамма у больных туберкулезом легких при различных клинических формах. Приведены данные, обосновывающие терапевтическое использование рекомбинантного интерферона-гамма, и результаты его клинического применения в качестве адьюванта к химиотерапии. Показаны перспективы иммунотерапии отечественным препаратом Ингарон больных туберкулезом легких с множественной лекарственной устойчивостью возбудителя.

The review analyzes of 69 publications and discusses treatment of drug-resistant tuberculosis from the standpoint of the influence on immune mechanisms that limit progression of inflammation and damage to lung tissue. Interferon-gamma is the most significant cytokine in tuberculosis infection pathogenesis. The article describes genotypic and phenotypic features of interferon-gamma production in various clinical forms of pulmonary tuberculosis. It presents the data supporting the therapeutic use of recombinant interferon-gamma and results of its clinical use as adjuvant treatment additionally to chemotherapy. It demonstrates the prospects for immunotherapy with Ingaron, the drug manufactured in Russia, for patients with multiple drug-resistant pulmonary tuberculosis.

лекарственно-устойчивый туберкулезтерапия хозяинаиммунная системаинтерферон-гаммаиммунотерапияdrug-resistant tuberculosishost-directed therapythe immune systeminterferon-gammaimmunotherapyReferencesБаласанянц Г.С., Рузанов Д.Ю. Иммуннотерапевтическая роль интерферона-γ при туберкулезе// Иммунология. – 2022. – Т. 43, № 3. – С. 343–351.Balasanyants G.S., Ruzanov D.Yu. `Immunotherapeutic role of interferon-γ at tuberculosis. Immunologiya, 2022, vol. 43, no. 3, pp. 343-351. (In Russ.)Воронкова О.В., Уразова О.И., Новицкий В.В., Стрелис А.К. Иммунопатология туберкулеза легких. Томск: Изд-во Том. ун-та; 2007.Voronkova O.V., Urazova O.I., Novitskiy V.V., Strelis A.K. Immunopatologiya tuberkuleza legkikh. [Immune pathology of pulmonary tuberculosis]. Tomsk, Tomsk University Publ., 2007.Есимова И. Е. Молекулярные механизмы дисрегуляции рецептор- и цитокин-опосредованной активации Т-лимфоцитов при туберкулезе легких.- Атореф…. Дисс. Д. м. н..- (14.03.03 – патологическая физиология, 03.03.04 – клеточная биология, цитология, гистология) – Томск – 2018. URL: https://search.rsl.ru/ru/record/01008715107 [Дата обращения 1 декабря 2023 г.]Esimova I.E. Molekulyarnyye mekhanizmy disregulyatsii retseptori tsitokin-oposredovannoy aktivatsii T-limfotsitov pri tuberkuleze legkikh. Avtoref. diss. dokt. med. nauk. [Molecular mechanisms of dysregulation of receptor- and cytokine-mediated activation of T-lymphocytes in pulmonary tuberculosis. Synopsis of Doct. Diss.]. Tomsk, 2018. Available: https://search.rsl.ru/ru/record/01008715107 Accessed December 1, 2023.Захарова М.В., Стаханов В.А., Мезенцева М.В. Особенности цитокинового профиля и интерферонового статуса больных инфильтративным туберкулезом легких// Инфекционные болезни. – 2011. – Т. 9,№ 1. – С. 47–50Zakharova M.V., Stakhanov V.A., Mezentseva M.V. Features of the cytokine profile and interferon status of patients with infiltrative pulmonary tuberculosis. Infectious Diseases (Infektsionnye Bolezni), 2011, vol. 9, no. 1, pp. 47-50. (In Russ.)Иванов А.К., Сологуб Т.В., Пантелеев А.М., Суханов Д.С., Романцов М.Г.,Коваленко А.Л. Комплексное лечение больных туберкулезом, инфицированных ВИЧ, с применением циклоферона// Экспер и клин фармакол. – 2010. – № 7. – С. 32–35.Ivanov A.K., Sologub T.V., Panteleev A.M., Sukhanov D.S., Romantsov M.G., Kovalenko A.L. Comprehensive treatment of HIV-positive tuberculosis patients with cycloferon. Eksper. I Klin Farmakol., 2010, no. 7, pp. 32-35. (In Russ.)Кетлинский С.А., Симбирцев А.С. Цитокины. СПб.: Фолиант; 2008.Ketlinskiy S.A., Simbirtsev A.S. Tsitokiny. [Cytokines]. St. Peterburg, Foliant Publ, 2008.Киселев О.И., Ершов Ф.И., Деева Э.Г. Интерферон-гамма: новый цитокин в клинической практике. Ингарон. Москва : Димитрейд График Групп; 2007.Kiselev O.I., Ershov F.I., Deeva E.G. Interferon-gamma: novy tsitokin v klinicheskoy praktike. Ingaron. [Interferon-gamma: a new cytokine in the clinical practice. Ingaron]. Moscow, Dimitreyd Graphic Group Publ., 2007.Кноринг Б.Е., Давыдова Н.И., Басек Т.Ф., Ница Н.А., Елькин А.В. Показатели иммунитета в зависимости от выраженности деструктивных изменений в легких// Медицинская иммунология. – 2012. – Т.14, № 4-5. – С.329-336.Knoring B.E., Davydova N.I., Basek T.F., Nitsa N.A., Elkin A.V. Immune indexes in patients with progressive fibrous-cavernous tuberculosis dependent on severity of destructive changes in the lungs. Medical Immunology (Russia), 2012, vol. 14, no. 4-5, pp. 329-336. (In Russ.)Линге И.А., Апт А.С. Нейтрофилы: неоднозначная роль в патогенезе туберкулеза // Инфекция и иммунитет. – 2021. –Т. 11,№ 5. – C. 809–819. https://doi.org/10.15789/2220-7619-ACR-1670Linge I.A., Apt A.S. A controversial role of neutrophils in tuberculosis infection pathogenesis. Infektsiya I Immunitet, 2021, vol. 11, no. 5, pp. 809-819. (In Russ.) https://doi.org/10.15789/2220-7619-ACR-1670Луцкий А.А., Жирков А.А., Лобзин Д.Ю. , Рао М., Алексеева Л.А., Мейрер М., Лобзин Ю.В.. Интерферон-γ: биологическая функция и значение для диагностики клеточного иммунного ответа// Журнал инфектологии. – 2015. – T.7, №4. – С.10-22.Lutsky A.A., Zhirkov A.A., Lobzin D.Yu., Rao M., Alekseeva L.A., Meyrer M., Lobzin Yu.V. Interferon-γ: biological function and application for study of cellular immune response. Journal Infektologii, 2015, vol. 7, no. 4, pp. 10-22. (In Russ.)Масленников А.А., Оболонкова Н.И. Эффективность ингарона в комплексной терапии больных деструктивным туберкулезом легких с бактериовыделением// Научный результат. Сер. Медицина и фармация. – 2016. – Т.2, № 7. – С. 10 – 16.Maslennikov A.A., Obolonkova N.I. The effectiveness of Ingaron in comprehensive therapy of patients with destructive pulmonary tuberculosis with bacterial excretion. Nauchnyy Rezultat. Ser. Meditsina I Farmatsiya, 2016, vol. 2, no. 7, pp. 10-16. (In Russ.)Можокина Г. Н., Самойлова А. Г., Васильева И. А., Русских А. Е. Препараты для краткосрочной химиотерапии лекарственно-устойчивого туберкулеза и их влияние на организм человека // Туберкулёз и болезни лёгких. – 2022. – Т. 100, № 8. – С. 54-64. http://doi.org/10.21292/2075-1230-2022-100-8-54-64Mozhokina G.N., Samoylova A.G., Vasilyeva I.A., Russkikh A.E. Medications for short-course chemotherapy of drug resistant tuberculosis and their effect on the host. Tuberculosis and Lung Diseases, 2022, vol. 100, no. 8, pp. 54-64. (In Russ.) http://doi.org/10.21292/2075-1230-2022-100-8-54-64Никулина Е.Л., Наследникова И.О., Уразова О.И., Воронкова О.В., Новицкий В.В., Некрасов Е.В., Филинюк О.В., Чурина Е.Г., Михеева К.О., Хасанова Р.Р., Серебрякова В.А., Сухаленцева Н.А. Аллельный полиморфизм гена IFNγ при туберкулезе легких// Медицинская иммунология. – 2010, – Т. 12, № 3, – С. 259-264Nikulina E.L., Naslednikova I.O., Urazova O.I., Voronkova O.V., Novitskiy V.V., Nekrasov E.V., Filinyuk O.V., Churina E.G., Mikheeva K. O.O., Khasanova R.R., Serebryakova V.A., Sukhalentseva N.A. Allelic polymorphism of the IFNγ gene in pulmonary tuberculosis. Meditsinskaya Immunologiya, 2010, vol. 12, no. 3, pp. 259-264. (In Russ.)Писаренко М.С. Особенности секреции интерферона-гамма при лекарственно-устойчивом туберкулезе легких // Фундаментальные исследования. – 2013. – Т.9, № 3. – С. 444-447; URL: https://fundamental-research.ru/ru/article/view?id=32371 [Дата обращения: 09.01.2023]Pisarenko M.S. Features of interferon-gamma secretion in drug resistant pulmonary tuberculosis. Fundamentalnye Issledovaniya, 2013, vol. 9, no. 3, pp. 444-447. (In Russ.) Available: https://fundamental-research.ru/ru/article/view?id=32371 Accessed January 09, 2023.Правада Н.С., Будрицкий А.М. Комплексная терапия с применением иммунотропных препаратов при туберкулезе и система интерферона-гамма// Вестник ВГМУ. – 2015. – Т. 4, № 4. С. 5–14.Pravada N.S., Budritskiy A.M. Comprehensive therapy with immunotropic drugs for tuberculosis and the interferon-gamma system. Vestnik VGMU, 2015, vol. 4, no. 4, pp. 5-14. (In Russ.)Распоряжение Правительства Российской Федерации от 12.10.2019 № 2406-р «Об утверждении перечня жизненно необходимых и важнейших лекарственных препаратов на 2020 год» с изменениями внесенными распоряжением Правительства РФ от 23 декабря 2021 г. № 3781-р вступающими в силу с 1 января 2022 года «Перечень жизненно необходимых и важнейших лекарственных препаратов для медицинского применения на 2022 год» URL:https://normativ.kontur.ru/document?moduleId=1&documentId=455400 [Дата обращения: 09.01.2024]Edict No. 2406-r On Approval of the List of Vital and Essential Drugs for 2020 by the Government of the Russian Federation dated October 12, 2019 as amended by Edict No. 3781-r On the List of Vital and Essential Drugs for Medical Use for 2022 by the Government of the Russian Federation dated December 23, 2021 coming into force on January 1, 2022. (In Russ.) Available: https://normativ.kontur.ru/document?moduleId=1&documentId=455400 Accessed January 09, 2024.Русских А. Е., Кутузова Д. М., Ловачева О. В., Самойлова А. Г., Васильева И. А. Краткосрочные схемы лечения больных туберкулезом с множественной лекарственной устойчивостью. Современная ситуация и дальнейшие перспективы // Туберкулез и болезни легких. ‒ 2020. ‒ Т. 98, № 12. ‒ С. 57-66.Russkikh A.E., Kutuzova D.M., Lovacheva O.V., Samoylova A.G., Vasilyeva I.A. Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives. Tuberculosis and Lung Diseases, 2020, vol. 98, no. 12, pp. 57-66. (In Russ.)Салина Т. Ю., Морозова Т. И. Особенности продукции цитокинов у больных туберкулезом легких// Клиническая лабораторная диагностика. – 2013. – № 3, – С.18 -20.Salina T.Yu., Morozova T.I. Specific cytokine production in pulmonary tuberculosis patients. Klinicheskaya Laboratornaya Diagnostika, 2013, no. 3, pp. 18-20. (In Russ.)Суханов Д.С. Иммунотропная терапия туберкулезной инфекции//Терапевтический архив. – 2013. – 3 . – С.110-117.Sukhanov D.S. Immunotropic therapy for tuberculosis infection. Terapevticheskiy Arkhiv, 2013, no. 3, pp. 110-117. (In Russ.)Уразова О.И., Есимова И.Е., Игнатова М.С., Новицкий В.В., Филинюк О.В. Синтез и секреция интерферона гамма при туберкулезе легких// Вестник науки Сибири. – 2014. – Т. 4, № 14. – С. 286 – 290.Urazova O.I., Esimova I.E., Ignatova M.S., Novitskiy V.V., Filinyuk O.V. Synthesis and secretion of interferon gamma in pulmonary tuberculosis. Vestnik Nauki Siberi, 2014, vol. 4, no. 14, pp. 286-290. (In Russ.)Хасанова Р.Р. Роль генотипа инфицирующего штамма Mycobacterium tuberculosis в иммунопатогенезе туберкулеза легких: автореф. дис. … канд. мед. наук. Томск, 2009. 24 с. URL: https://search.rsl.ru/ru/record/01003466023 [Дата обращения: 06.09.2023].Khasanova R.R. Rol genotipa infitsiruyushchego shtamma Mycobacterium tuberculosis v immunopatogeneze tuberkuleza legkikh. Avtoref. dis. kand. med. nauk. [The role of the genotype of the infecting strain of Mycobacterium tuberculosis in the immunopathogenesis of pulmonary tuberculosis. Sysnopsis of Doct. Diss.]. Tomsk, 2009, 24 p. Available: https://search.rsl.ru/ru/record/01003466023 Accessed September 06, 2023.Хрянин А. А., Решетников О. В. Интерферон- гамма: горизонты терапии// Антибиотики и химиотерапия. – 2016. – Т. 61, № 3-4. – С.35-40.Khryanin A.A., Reshetnikov O.V. Interferon-gamma: treatment horizons. Antibiotiki i Khimioterapiya, 2016, vol. 61, no. 3-4, pp. 35-40. (In Russ.)Чурина Е.Г., Уразова О.И., Новицкий В.В., Ситникова А.В., Бармина С.Э. Функциональный полиморфизм генов провоспалительных цитокинов при туберкулезе легких // Медицинская иммунология. – 2019. –Т. 21, № 1. – С. 149-156.Churina E.G., Urazova O.I., Novitskiy V.V., Sitnikova A.V., Barmina S.E.Functional polymorphism of proinflammatory cytokine genes in pulmonary tuberculosis. Meditsinskaya Immunologiya, 2019, vol. 21, no. 1, pp. 149-156. (In Russ.)Abate G., Hoft D.F. Immunotherapy for tuberculosis: future prospects // Immunotargets Ther. – 2016. – Vol. 20, № 5. – Р.37-45. https://doi.org/10.2147/ITT.S81892Abate G., Hoft D.F. Immunotherapy for tuberculosis: future prospects. Immunotargets Ther., 2016, vol. 20, no. 5, pp. 37-45. https://doi.org/10.2147/ITT.S81892Ahmad S. Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection // Clin. Dev. Immunol. – 2011. – Vol. 2011. – 1–17. https://doi.org/10.1155/2011/814943Ahmad S. Pathogenesis, immunology, and diagnosis of latent Mycobacterium tuberculosis infection. Clin. Dev. Immunol., 2011, vol. 2011, pp. 1-17. https://doi.org/10.1155/2011/814943Arrigoni R., Ballini A., Topi S., Bottalico L., Jirillo E., Santacroce L. Antibiotic Resistance to Mycobacterium tuberculosis and Potential Use of Natural and Biological Products as Alternative Anti-Mycobacterial Agents // Antibiotics (Basel). – 2022. – Vol.11, № 10. – Р.1431. https://doi.org/10.3390/antibiotics11101431Arrigoni R., Ballini A., Topi S., Bottalico L., Jirillo E., Santacroce L. Antibiotic resistance to Mycobacterium tuberculosis and potential use of natural and biological products as alternative anti-mycobacterial agents. Antibiotics (Basel), 2022, vol. 11, no. 10, pp. 1431. https://doi.org/10.3390/antibiotics11101431Bergman P, Raqib R., Rekha R.S., Agerberth B. and Gudmundsson GH (2020) Host Directed Therapy Against Infection by Boosting Innate Immunity // Front. Immunol. – 2020. – №11. – Р.1209. https://doi.org/10.3389/fimmu.2020.01209Bergman P, Raqib R., Rekha R.S., Agerberth B. and Gudmundsson G.H. Host directed therapy against infection by boosting innate immunity. Front. Immunol., 2020, no. 11, pp. 1209. https://doi.org/10.3389/fimmu.2020.01209Berns S.A.,Isakova J.A., Pekhtereva P.I. Therapeutic potential of interferon-gamma in tuberculosis // ADMET DMPK. – 2022. – Vol.10, № 1. – Р.63-73.Berns S.A., Isakova J.A., Pekhtereva P.I. Therapeutic potential of interferon-gamma in tuberculosis. ADMET DMPK, 2022, vol. 10, no. 1, pp. 63-73.Bulat-Kardum L., Etokebe G.E., Knezevic J., Balen S., Matakovic-Mileusnic N., Zaputovic L., Pavelic J., Beg-Zec Z., Dembic Z. Interferon-gamma receptor-1 gene promoter polymorphisms (G-611A; T-56C) and susceptibility to tuberculosis // Scand. J. Immunol. –2006. – Vol. 63, №2. – С. 142-50. https://doi.org/10.1111/j.1365-3083.2005.01694.xBulat-Kardum L., Etokebe G.E., Knezevic J., Balen S., Matakovic-Mileusnic N., Zaputovic L., Pavelic J., Beg-Zec Z., Dembic Z. Interferon-gamma receptor-1 gene promoter polymorphisms (G-611A; T-56C) and susceptibility to tuberculosis. Scand. J. Immunol., 2006, vol. 63, no. 2, pp. 142-50. https://doi.org/10.1111/j.1365-3083.2005.01694.xCahill C., Phelan J.J., Keane J. Understanding and Exploiting the Effect of Tuberculosis Antimicrobials on Host Mitochondrial Function and Bioenergetics // Front. Cell. Infect. –2020. – №10. –P.493 https://doi.org/10.3389/fcimb.2020.00493Cahill C., Phelan J.J., Keane J. Understanding and exploiting the effect of tuberculosis antimicrobials on host mitochondrial function and bioenergetics. Front. Cell. Infect., 2020, no. 10, pp. 493. https://doi.org/10.3389/fcimb.2020.00493Casanova J.L., Abel L. Genetic dissection of immunity to mycobacteria: the human model // Annu. Rev. Immunol. – 2002. – № 20. – P.581–620. https://doi.org/10.1146/annurev.immunol.20.081501.125851Casanova J.L., Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu. Rev. Immunol., 2002, no. 20, pp. 581-620. https://doi.org/10.1146/annurev.immunol.20.081501.125851Condos R., Raju B., Canova A., Zhao B.Y., Weiden M., Rom W.N., Pine R. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients // Infect. Immun. – 2003. – №71. – P.2058 –2064. https://doi.org/10.1128/IAI.71.4.2058-2064.2003Condos R., Raju B., Canova A., Zhao B.Y., Weiden M., Rom W.N., Pine R. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect. Immun., 2003, no. 71, pp. 2058-2064. https://doi.org/10.1128/IAI.71.4.2058-2064.2003Condos R., Rom WN & Schluger NW. 1997 Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol // Lancet. –1997. – № 349. – P.1513–1515Condos R., Rom W.N., Schluger N.W. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet, 1997, no. 349, pp. 1513-1515. https://doi.org/10.1016/S0140-6736(96)12273-XCooper A. M., Dalton D. K., Stewart T. A., Griffin J. P., Russell D. G., Orme I. M. Disseminated tuberculosis in interferon gamma gene-disrupted mice // J. Exp. Med. – 1993. – № 178. – P. 2243-2247Cooper A.M., Dalton D.K., Stewart T.A., Griffin J.P., Russell D.G., Orme I.M. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med., 1993, no. 178, pp. 2243-2247.Cox D. J., Coleman A. M., Gogan K. M., Phelan J. J., Maoldomhnaigh O. C., Dunne P. J., et al. Inhibiting histone deacetylases in human macrophages promotes glycolysis, IL-1β, and T helper cell responses to Mycobacterium tuberculosis // Front. Immunol. – 2020. – №11. – P.1609Cox D.J., Coleman A.M., Gogan K.M., Phelan J.J., Maoldomhnaigh O.C., Dunne P.J. et al. Inhibiting histone deacetylases in human macrophages promotes glycolysis, IL-1β, and T helper cell responses to Mycobacterium tuberculosis. Front. Immunol., 2020, no. 11, pp.1609.Darnell J.E. Jr, Kerr I.M., Stark G.R. Jak–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. –1994. – Vol.264, №5164. – Р.1415-21.Darnell J.E. Jr, Kerr I.M., Stark G.R. Jak–STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 1994, vol. 264, no. 5164, pp. 1415-21.Dawson R., Condos R., Tse D., Huie M.L., Ress S., Tseng C.H., Brauns C., Weiden M., Hoshino Y., Bateman E., Rom W.N. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis //PLoS One. – 2009. – №4:e6984. https://doi.org/10.1371/journal.pone.0006984Dawson R., Condos R., Tse D., Huie M.L., Ress S., Tseng C.H., Brauns C., Weiden M., Hoshino Y., Bateman E., Rom W.N. Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One, 2009, no. 4, pp. e6984. https://doi.org/10.1371/journal.pone.0006984Drain PK, Bajema KL, Dowdy D, et al. Incipient and Subclinical Tuberculosis: a Clinical Review of Early Stages and Progression of Infection // Clin. Microbiol. Rev. – 2018. – Vol. 31, № 4. – Р. e00021–18.Drain P.K., Bajema K.L., Dowdy D. et al. Incipient and subclinical tuberculosis: a clinical review of early stages and progression of infection. Clin. Microbiol. Rev., 2018, vol. 31, no. 4, pp. e00021-18.Ehrt S., Schnappinger D., Bekiranov S., Drenkow J., Shi S., Gingeras T.R., Gaasterland T., Schoolnik G., Nathan C. Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase // J. Exp. Med. –2001. – №194. – Р.1123–1140. https://doi.org/10.1084/jem.194.8.1123Ehrt S., Schnappinger D., Bekiranov S., Drenkow J., Shi S., Gingeras T.R., Gaasterland T., Schoolnik G., Nathan C. Reprogramming of the macrophage transcriptome in response to interferon-gamma and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J. Exp. Med., 2001, no. 194, pp. 1123-1140. https://doi.org/10.1084/jem.194.8.1123Etokebe G.E., Bulat-Kardum L., Johansen M.S., Knezevic J., Balen S., Matakovic-Mileusnic N., Matanic D., Flego V., Pavelic J., Beg-Zec Z. and Dembic, Z. Interferon-γ Gene (T874A and G2109A) Polymorphisms Are Associated With Microscopy-positive Tuberculosis //Scandinavian Journal of Immunology. – №63. – Р.136-141.Etokebe G.E., Bulat-Kardum L., Johansen M.S., Knezevic J., Balen S., Matakovic-Mileusnic N., Matanic D., Flego V., Pavelic J., Beg-Zec Z., Dembic Z. Interferon-γ gene (T874A and G2109A) polymorphisms are associated with microscopy-positive tuberculosis. Scandinavian Journal of Immunology, no. 63, pp. 136-141.Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection // J. Exp. Med. –1993. – №178. – Р.2249 –2254. https://doi.org/10.1084/jem.178.6.2249Flynn J.L., Chan J., Triebold K.J., Dalton D.K., Stewart T.A., Bloom B.R. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med., 1993, no. 178, pp. 2249 -2254. https://doi.org/10.1084/jem.178.6.2249Fortes A., Pereira K., Antas PRZ., Franken CLMC., Dalcolmo M., Ribeiro-Carvalho M.M., Cunha K.S, Geluk A., Kritski A., Kolk A., Klatser P., Sarno E.N., Ottenhoff THM., Sampaio EP. Detection of in vitro interferon-γ and serum tumour necrosis factor-α in multidrug-resistant tuberculosis patients //Clin Exp Immunol. –2005. – Vol. 141, № 3. – Р. 541–548. . https://doi.org/10.1111/j.1365-2249.2005.02872.xFortes A., Pereira K., Antas P.R.Z., Franken C.L.M.C., Dalcolmo M., Ribeiro-Carvalho M.M., Cunha K.S, Geluk A., Kritski A., Kolk A., Klatser P., Sarno E.N., Ottenhoff T.H.M., Sampaio E.P. Detection of in vitro interferon-γ and serum tumour necrosis factor-α in multidrug-resistant tuberculosis patients. Clin. Exp. Immunol., 2005, vol. 141, no. 3, pp. 541-548. https://doi.org/10.1111/j.1365-2249.2005.02872.xGenestet C., Bernard-Barret F., Hodille E., Ginevra C., Ader F., Goutelle S., Lina G., Dumitrescu O; Lyon TB study group. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophage// Tuberculosis (Edinb). –2018. – №111. – Р. 67-70.Genestet C., Bernard-Barret F., Hodille E., Ginevra C., Ader F., Goutelle S., Lina G., Dumitrescu O., Lyon TB study group. Antituberculous drugs modulate bacterial phagolysosome avoidance and autophagy in Mycobacterium tuberculosis-infected macrophage. Tuberculosis (Edinb.), 2018, no. 111, pp. 67-70.Ghanavi J., Farnia P., Velayati A.A. The role of interferon-gamma and interferon-gamma receptor in tuberculosis and nontuberculous mycobacterial infections // Int J Mycobacteriol. –2021. – Vol.10, № 4. – Р.349-357.Ghanavi J., Farnia P., Velayati A.A. The role of interferon-gamma and interferon-gamma receptor in tuberculosis and nontuberculous mycobacterial infections. Int. J. Mycobacteriol., 2021, vol. 10, no. 4, pp. 349-357.Hawn T. R., Matheson A. I., Maley S.N., Vandalc O. Host-Directed Therapeutics for Tuberculosis: Can We Harness the Host? // Microbiology and Molecular Biology Reviews . –2013.- V. 77, N. 4. – Р. 608 – 627.Hawn T.R., Matheson A.I., Maley S.N., Vandalc O. Host-directed therapeutics for tuberculosis: can we harness the host? Microbiology and Molecular Biology Reviews, 2013, vol. 77, no. 4 pp. 608-627.Kadura S., King N., Nakhoul M., Zhu H., Theron G., Köser C.U., Farhat M. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid // J Antimicrob Chemother. – 2020. – Vol.75, № 8. – Р.2031-2043.Kadura S., King N., Nakhoul M., Zhu H., Theron G., Köser C.U., Farhat M. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J. Antimicrob. Chemother., 2020, vol. 75, no. 8, pp. 2031-2043.Kaufmann S. H. E., Dorhoi A., Hotchkiss R. S., Bartenschlager R. Host-directed potent target of HDTs is immune checkpoints. These immunomodulatory therapeutic strategies have been studied extensively therapies for bacterial and viral infections // Nat. Rev. Drug Discov. – 2018. – № 17. – Р. 35–56.Kaufmann S.H.E., Dorhoi A., Hotchkiss R.S., Bartenschlager R. Host-directed potent target of HDTs is immune checkpoints. These immunomodulatory therapeutic strategies have been studied extensively therapies for bacterial and viral infections. Nat. Rev. Drug Discov., 2018, no. 17, pp. 35-56.Khan T.A., Mazhar H., Saleha S., Tipu H.N., Muhammad N., Abbas M.N. Interferon-Gamma Improves Macrophages Function against M. tuberculosis in Multidrug-Resistant Tuberculosis Patients // Chemother Res Pract. – 2016. – № 2016. – Р.7295390. https://doi.org/10.1155/2016/7295390Khan T.A., Mazhar H., Saleha S., Tipu H.N., Muhammad N., Abbas M.N. Interferon-gamma improves macrophages function against M. tuberculosis in multidrug-resistant tuberculosis patients. Chemother. Res. Pract., 2016, no. 2016, pp. 7295390. https://doi.org/10.1155/2016/7295390Khoshnood S., Goudarzi M., Taki E., Darbandi A., Kouhsari E., Heidary M., Motahar M., Moradi M., Bazyar H. Bedaquiline: Current status and future perspectives // J Glob Antimicrob Resist. – 2021. – № 25. – Р.48-59.Khoshnood S., Goudarzi M., Taki E., Darbandi A., Kouhsari E., Heidary M., Motahar M., Moradi M., Bazyar H. Bedaquiline: Current status and future perspectives. J. Glob. Antimicrob. Resist., 2021, no. 25, pp. 48-59.Kilinc G., Saris A., Ottenhoff T.H.M., Haks M.C. Host-directed therapy to combat mycobacterial infections // Immunological Reviews. – 2021. – Vol. 301, № 1. – Р.62-83.Kilinc G., Saris A., Ottenhoff T.H.M., Haks M.C. Host-directed therapy to combat mycobacterial infections. Immunological Reviews, 2021, vol. 301, no. 1, pp. 62-83.Kim Y-R., Yang C-S. Host-Directed Therapeutics as a Novel Approach for Tuberculosis Treatment // J. Microbiol. Biotechnol. – 2017. – Vol. 27, №9. – Р. 1549–1558.Kim Y.R., Yang C.S. Host-directed therapeutics as a novel approach for tuberculosis treatment. J. Microbiol. Biotechnol., 2017, vol. 27, no. 9, pp. 1549-1558.Koh W.J., Kwon O.J., Suh G.Y., Chung M.P., Kim H., Lee N.Y., Kim T.S., Lee K.S. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis // J Korean Med Sci. – 2004. – Vol.19, № 2. –Р.167-71.Koh W.J., Kwon O.J., Suh G.Y., Chung M.P., Kim H., Lee N.Y., Kim T.S., Lee K.S. Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis. J. Korean Med. Sci., 2004, vol. 19, no. 2, pp. 167-71.MacMicking JD. Interferon-inducible effector mechanisms in cell-autonomous immunity // Nat. Rev. Immunol. – 2012. – Vol.12. – Р.367–382.MacMicking J.D. Interferon-inducible effector mechanisms in cell-autonomous immunity. Nat. Rev. Immunol., 2012, vol. 12, pp. 367-382.Manca C., Koo M-S, Peixoto B., Fallows D., Kaplan G., Subbian S. 2013. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection //PLOS ONE. –2013. – № 8. –Р.e74082.Manca C., Koo M.S, Peixoto B., Fallows D., Kaplan G., Subbian S. 2013. Host targeted activity of pyrazinamide in Mycobacterium tuberculosis infection. PLOS ONE, 2013, no. 8, pp. e74082.Martinot A.J. Microbial Offense vs Host Defense: Who Controls the TB Granuloma? //Vet. Pathol. – 2018. – № 55. – Р.14–26.Martinot A.J. Microbial Offense vs Host Defense: Who сontrols the TB granuloma? Vet. Pathol., 2018, no. 55, pp. 14-26.Milanés-Virelles M.T., García-García I., Santos-Herrera Y., ValdésQuintana M., Valenzuela-Silva C.M., Jiménez-Madrigal G., RamosGómez T.I., Bello-Rivero I., Fernández-Olivera N., Sánchez-de la Osa R.B., Rodríguez-Acosta C., González-Méndez L., Martínez-Sánchez G., López-Saura P.A., MACGAM Study Group. Adjuvant interferon gamma in patients with pulmonary atypical mycobacteriosis: a randomized, double-blind, placebo-controlled study //BMC Infect. Dis. – 2008. – Vol.8, №17. https://doi.org/10.1186/1471-2334-8-17.Milanés-Virelles M.T., García-García I., Santos-Herrera Y., ValdésQuintana M., Valenzuela-Silva C.M., Jiménez-Madrigal G., RamosGómez T..I, Bello-Rivero .I, Fernández-Olivera N., Sánchez-de la Osa R.B., Rodríguez-Acosta C., González-Méndez L., Martínez-Sánchez G., López-Saura P.A., MACGAM Study Group. Adjuvant interferon gamma in patients with pulmonary atypical mycobacteriosis: a randomized, double-blind, placebo-controlled study. BMC Infect. Dis., 2008, vol. 8, no. 17. https://doi.org/10.1186/1471-2334-8-17.Mily A., Rekha R.S., Kamal S.M., Arifuzzaman A.S., Rahim Z., Khan L, et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial // PLoS ONE. – 2015. – № 10. – Р.e0138340.Mily A., Rekha R.S., Kamal S.M., Arifuzzaman A.S., Rahim Z., Khan L, et al. Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial. PLoS ONE, 2015, no. 10, pp. e0138340.Paik S., Kim J.K., Chung C., Jo E.K. Autophagy: A new strategy for host-directed therapy of tuberculosis //Virulence. –2019. – Vol.10, № 1. – Р. 448-459.Paik S., Kim J.K., Chung C., Jo E.K. Autophagy: a new strategy for host-directed therapy of tuberculosis. Virulence, 2019, vol. 10, no. 1, pp. 448-459.Park H.E., Lee W., Shin M.K., Shin S.J. Understanding the Reciprocal Interplay Between Antibiotics and Host Immune System: How Can We Improve the Anti-Mycobacterial Activity of Current Drugs to Better Control Tuberculosis? // Front Immunol. – 2021. – № 12. – Р. 703060.Park H.E., Lee W., Shin M.K., Shin S.J. Understanding the reciprocal interplay between antibiotics and host immune system: how can we improve the anti-mycobacterial activity of current drugs to better control tuberculosis? Front Immunol., 2021, no. 12, pp. 703060.Pearl J.E., Saunders B., Ehlers S., Orme I.M., Cooper A.M. Inflammation and lymphocyte activation during mycobacterial infection in the interferon-gamma-deficient mouse //Cell Immunol. – 2001. – Vol.211, № 1. – Р.43-50.Pearl J.E., Saunders B., Ehlers S., Orme I.M., Cooper A.M. Inflammation and lymphocyte activation during mycobacterial infection in the interferon-gamma-deficient mouse. Cell Immunol., 2001, vol. 211, no. 1, pp. 43-50.Reichmuth M.L., Hömke R., Zürcher K., Sander P., Avihingsanon A., Collantes J. Natural polymorphisms in Mycobacterium tuberculosis conferring resistance to delamanid in drugnaive patients // Antimicrob Agents Chemother. –2020. – № 64. – Р.e00513-20.Reichmuth M.L., Hömke R., Zürcher K., Sander P., Avihingsanon A., Collantes J. Natural polymorphisms in Mycobacterium tuberculosis conferring resistance to delamanid in drugnaive patients. Antimicrob. Agents Chemother., 2020, no. 64, pp. e00513-20.Restrepo BI. Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients // Tuberculosis (Edinb). – 2016. – № 101S. – Р.S69-S72.Restrepo B.I. Metformin: Candidate host-directed therapy for tuberculosis in diabetes and non-diabetes patients. Tuberculosis (Edinb.), 2016, no. 101S, pp. S69-S72.Russell S. L., Lamprecht D. A., Mandizvo T., Jones T. T., Naidoo V., Addicott K. W., et al. Compromised Metabolic Reprogramming Is an Early Indicator of CD8(+) T Cell Dysfunction during Chronic Mycobacterium tuberculosis Infection // Cell Rep. – 2019. – Vol. 29, № 11. –Р. 3564-3579.e5.Russell S.L., Lamprecht D.A., Mandizvo T., Jones T.T., Naidoo V., Addicott K.W. et al. Compromised metabolic reprogramming is an early indicator of CD8(+) T cell dysfunction during chronic Mycobacterium tuberculosis infection. Cell Rep., 2019, vol. 29, no. 11, pp. 3564-3579.e5.Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses //Adv Immunol. – 2007. – № 96. – Р.41-101.Schoenborn J.R., Wilson C.B. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol., 2007, no. 96, pp. 41-101.Sekyere J.O., Maningi N., Fourie P.B. Mycobacterium tuberculosis, antimicrobials, immunity, and lung–gut microbiota crosstalk: Current updates and emerging advances // Ann. N. Y. Acad. Sci. – 2020. –№ 1467. – Р. 21–47.Sekyere J.O., Maningi N., Fourie P.B. Mycobacterium tuberculosis, antimicrobials, immunity, and lung–gut microbiota crosstalk: Current updates and emerging advances. Ann. N. Y. Acad. Sci., 2020, no. 1467, pp. 21-47.Shanmuganathan G., Orujyan D., Narinyan W., Poladian N., Dhama S., Parthasarathy A., Ha A., Tran D., Velpuri P., Nguyen K.H., Venketaraman V. Role of Interferons in Mycobacterium tuberculosis Infection //Clin Pract. – 2022. – Vol.12, № 5. – Р.788-796.Shanmuganathan G., Orujyan D., Narinyan W., Poladian N., Dhama S., Parthasarathy A., Ha A., Tran D., Velpuri P., Nguyen K.H., Venketaraman V. Role of interferons in Mycobacterium tuberculosis infection. Clin. Pract., 2022, vol. 12, no. 5, pp. 788-796.Suárez-Méndez R., García-García I., Fernández-Olivera N., Valdés-Quintana M., Milanés-Virelles M.T, Carbonell D., Machado-Molina D., Valenzuela-Silva C.M, López-Saura P. Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study // BMC Infect Dis . – 2004. – № 4. – Р. 44. https://doi.org/10.1186/1471-2334-4-44Suárez-Méndez R., García-García I., Fernández-Olivera N., Valdés-Quintana M., Milanés-Virelles M.T, Carbonell D., Machado-Molina D., Valenzuela-Silva C.M, López-Saura P. Adjuvant interferon gamma in patients with drug – resistant pulmonary tuberculosis: a pilot study. BMC Infect. Dis., 2004, no. 4, pp. 44. https://doi.org/10.1186/1471-2334-4-44WHO consolidated guidelines on drug-resistant tuberculosis treatment © World Health Organization 2019; Working Group on New TB Drugs. PMID: 30946559 ISBN 978-92-4-155052-9WHO consolidated guidelines on drug-resistant tuberculosis treatment © World Health Organization 2019; Working Group on New TB Drugs. PMID: 30946559 ISBN 978-92-4-155052-9WHO Updates Definition of XDR-TB https://www.who.int/publications/i/item/meeting-report-of-the-who-expert-consultation-on-the-definitionof-extensively-drug-resistant-tuberculosis Available at : https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis [Accessed 12 dec 2023]WHO Updates Definition of XDR-TB. https://www.whoint/publications/i/item/meeting-report-of-the-who-expert.consultation-on-the-definitionof-extensively-drug-resistant-tuberculosis Available: https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis Accessed December 12, 2023.

The authors declare that there are no conflicts of interest present.